Table 3: Utility values used in the model.

Mean (SE)Source

Utility values for PFS and PPS, mean (SE)
  Preprogression
  Pazopanib0.674 (0.015)PALETTE
  Placebo0.678 (0.024)PALETTE
  Postprogression
  Pazopanib0.568 (0.044)PALETTE
  Placebo0.636 (0.040)PALETTE
Estimated disutility values for AEs (SE)
 Alopecia0.045 (0.015)Nafees et al. 2008 [27]
 Anemia/hemoglobin0.119 (0.023)Swinburn et al. 2010 [28]
 Asthenia/fatigue 0.262 (0.027)Shingler et al. 2013 [26]
 Cardiovascular (cardiac toxicity/left ventricular dysfunction)0.2 (0)Assumption
 Decreased appetite/anorexia/weight decreased0.2 (0)Assumption
 Diarrhea0.327 (0.028)Shingler et al. 2013 [26]
 Edema0.2 (0)Assumption
 Febrile neutropenia0.09 (0.016)Nafees et al. 2008 [27]
 Leucopoenia/neutropenia/neutrophils/thrombocytopenia/low platelets0.09 (0.015)Nafees et al. 2008 [27]
 Liver toxicity (ALT/AST elevation)0Assumption
 Hypertension 0.153 (0.024)Swinburn et al. 2010 [28]
 Myalgia/muscle pain/neurotoxicity/peripheral sensory neuropathy0.236 (0.025)Shingler et al. 2013 [26]
 Nausea/vomiting 0.357 (0.026)Shingler et al. 2013 [26]
 Pulmonary (dyspnea/pleural effusion/pneumothorax/pulmonary toxicity)0.242 (0.026)Shingler et al. 2013 [26]

AEs: adverse events; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HR: hazard ratio; OS: overall survival; PFS: progression-free survival; PPS: postprogression survival; SE: standard error.